SCHEMBL16023779

SCHEMBL16023779

Cc1coc2c1C(=O)C(=O)c1c-2ccc2c1CCC(C)C2

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 9/20 0.60
▸ TDO2 P48775 8/20 0.60
▸ EED O75530 6/20 0.58
▸ SUZ12 Q15022 6/20 0.58
▸ EZH2 Q15910 6/20 0.58
▸ RBBP4 Q09028 1/20 0.58
▸ RBBP7 Q16576 1/20 0.58
▸ HIF1A Q16665 3/20 0.55
▸ EPAS1 Q99814 3/20 0.55
▸ CES2 O00748 2/20 0.55
▸ POLB P06746 2/20 0.55
▸ MAPT P10636 2/20 0.55
▸ CES1 P23141 2/20 0.55
▸ PTPN6 P29350 2/20 0.55
▸ PTPN11 Q06124 2/20 0.55
▸ NSD1 Q96L73 2/20 0.55
▸ TDP1 Q9NUW8 2/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ APAF1 O14727 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16023775 0.90 IDO1 (0.57) IDO1TDO2EEDSUZ12EZH2
SCHEMBL16023774 0.81 EED (0.66) IDO1TDO2EEDSUZ12EZH2
SCHEMBL4114682 0.79 EED (0.56) IDO1TDO2EEDSUZ12EZH2
SCHEMBL16421134 0.79 EED (0.56) IDO1TDO2EEDSUZ12EZH2
SCHEMBL16023776 0.75 EED (0.65) IDO1TDO2EEDSUZ12EZH2
SCHEMBL30923422 0.75 IDO1 (1.00) IDO1TDO2EEDSUZ12EZH2
SCHEMBL30978884 0.74 IDO1 (0.61) IDO1TDO2EEDSUZ12EZH2
SCHEMBL14417695 0.74 EED (1.00) IDO1TDO2EEDSUZ12EZH2
SCHEMBL16152287 0.74 EED (1.00) IDO1TDO2EEDSUZ12EZH2
SCHEMBL14417701 0.74 EED (1.00) IDO1TDO2EEDSUZ12EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160022625-A1 TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE THE UNIVERSITY OF AKRON 2016-01-28 — — US disclosed
US-20160022625-A1 TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE THE UNIVERSITY OF AKRON 2016-01-28 — — US disclosed
WO-2014138357-A1 NOVEL TASHINONE DRUGS FOR ALZHEIMER DISEASE THE UNIVERSITY OF AKRON (US) 2014-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022625-A1 TASHINONES AND THEIR DERIVATIVES: NOVEL EXCELLENT DRUGS FOR ALZHEIMER DISEASE APP, HTT, PSEN1 IDO1 3609/4885TDO2 2457/4885EED 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback